WO2002000241A3 - Compositions et procedes pour reguler le cycle cellulaire - Google Patents

Compositions et procedes pour reguler le cycle cellulaire Download PDF

Info

Publication number
WO2002000241A3
WO2002000241A3 PCT/EP2001/008096 EP0108096W WO0200241A3 WO 2002000241 A3 WO2002000241 A3 WO 2002000241A3 EP 0108096 W EP0108096 W EP 0108096W WO 0200241 A3 WO0200241 A3 WO 0200241A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
cell cycle
polypeptide
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/008096
Other languages
English (en)
Other versions
WO2002000241A2 (fr
Inventor
Didier Branellec
Elisabeth Lavenne
Roux Aude Le
Abderrahim Mahfoudi
Harris Perlman
Kenneth Walsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to AU2001289652A priority Critical patent/AU2001289652A1/en
Publication of WO2002000241A2 publication Critical patent/WO2002000241A2/fr
Publication of WO2002000241A3 publication Critical patent/WO2002000241A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne en règle générale des compositions et des procédés pour réguler le cycle cellulaire, notamment l'apoptose. La présente invention concerne plus particulièrement des compositions et des procédés faisant appel à un polypeptide Ki ou à un gène Ki pour réguler le cycle cellulaire, notamment l'apoptose, dans des cellules, in vitro, ex vivo ou in vivo. Ladite invention porte également sur des compositions, des vecteurs, des cellules et des éléments similaires, qui peuvent être utilisés pour mettre en oeuvre les procédés susmentionnés. Cette invention peut être appliquée pour protéger des cellules de l'apoptose, ou bien pour induire ou promouvoir l'apoptose dans des cellules, dans différentes conditions physio-pathologiques.
PCT/EP2001/008096 2000-06-28 2001-06-22 Compositions et procedes pour reguler le cycle cellulaire Ceased WO2002000241A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001289652A AU2001289652A1 (en) 2000-06-28 2001-06-22 Compositions and methods for regulating the cell cycle using a ki gene or polypeptide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21479000P 2000-06-28 2000-06-28
US60/214,790 2000-06-28

Publications (2)

Publication Number Publication Date
WO2002000241A2 WO2002000241A2 (fr) 2002-01-03
WO2002000241A3 true WO2002000241A3 (fr) 2002-10-17

Family

ID=22800421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/008096 Ceased WO2002000241A2 (fr) 2000-06-28 2001-06-22 Compositions et procedes pour reguler le cycle cellulaire

Country Status (2)

Country Link
AU (1) AU2001289652A1 (fr)
WO (1) WO2002000241A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9560984B2 (en) 2009-10-29 2017-02-07 The Nielsen Company (Us), Llc Analysis of controlled and automatic attention for introduction of stimulus material

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016459A1 (fr) * 1995-10-31 1997-05-09 Rhone-Poulenc Rorer S.A. Application de la proteine gax au traitement de cancers
WO1998017686A1 (fr) * 1996-10-18 1998-04-30 Rhone-Poulenc Rorer S.A. Polypeptides comprenant des domaines de la proteine gax, impliques dans la repression de transcription et/ou interagissant avec d'autres proteines, acides nucleiques correspondants et leurs utilisations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016459A1 (fr) * 1995-10-31 1997-05-09 Rhone-Poulenc Rorer S.A. Application de la proteine gax au traitement de cancers
WO1998017686A1 (fr) * 1996-10-18 1998-04-30 Rhone-Poulenc Rorer S.A. Polypeptides comprenant des domaines de la proteine gax, impliques dans la repression de transcription et/ou interagissant avec d'autres proteines, acides nucleiques correspondants et leurs utilisations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CIRCULATION, (1996) VOL. 94, NO. 8 SUPPL., PP. I472. MEETING INFO.: 69TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION NEW ORLEANS, LOUISIANA, USA NOVEMBER 10-13, 1996 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; MAHFOUDI, ABDERRAHIM (1) ET AL: "Identification of a repressor domain in the growth arrest homeobox gene (GAX) that interacts with the nuclear antigen Ki.", XP002034391, retrieved from STN *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9560984B2 (en) 2009-10-29 2017-02-07 The Nielsen Company (Us), Llc Analysis of controlled and automatic attention for introduction of stimulus material

Also Published As

Publication number Publication date
AU2001289652A1 (en) 2002-01-08
WO2002000241A2 (fr) 2002-01-03

Similar Documents

Publication Publication Date Title
WO2004044158A3 (fr) Cultures de cellules souches embryonnaires humaines, et compositions et procedes de culture correspondants
WO2004029219A3 (fr) Interference arn basee sur les cellules, et procedes et compositions s'y rapportant
AU2003216058A8 (en) Mammalian neural stem cells, compositions and uses thereof
WO2000053724A3 (fr) Compositions et procedes convenant a la modification de la transcription de genes
WO2002074969A3 (fr) Regions se liant a la matrice nucleaire (mar) et procedes d'utilisation de celles-ci
ZA200006594B (en) DSRNA-mediated regulation of gene expression in plants.
WO2001021766A3 (fr) Procedes et dispositifs permettant d'obtenir des cellules de lignee non hematopoietique a partir de cellules de progeniteurs hematopoietiques
AU2002319780A1 (en) Alternative compositions and methods for the culture of stem cells
AU2002301347A1 (en) Embryonic stem cells and neural progenitor cells derived therefrom
WO2004015077A3 (fr) Compositions et methodes de differentiation neuronale de cellules souches embryonnaires humaines
WO2001004282A3 (fr) Vecteurs anti-cancereux de replication
CA2429679A1 (fr) Gene hd3a induisant la floraison d'une plante et utilisation associee
WO2004007664A3 (fr) Vecteurs d'acides nucleiques
DK1645626T3 (da) Cellelinie
WO2002060914A3 (fr) Identification de nouveaux petits arn et orf de e. coli utilises comme mediateurs de la regulation cellulaire et intercellulaire
WO2002034890A3 (fr) Cellules souches pluripotentes
WO2004063341A3 (fr) Cellules niches de cellules souches hematopoietiques
WO2004044127A3 (fr) Populations de cellules souches
WO2002000241A3 (fr) Compositions et procedes pour reguler le cycle cellulaire
AU8371501A (en) Manipulation of plant senescence using an MYB gene promoter and cytokinin biosyntyhesis genes
WO2002086112A3 (fr) Molecules d'acide nucleique codant des enzymes degradant l'amidon
WO2001018192A3 (fr) Vecteurs synthetiques propres, plasmides, vegetaux transgeniques et fractions de vegetaux les renfermant, et methodes d'obtention
HK1042112A1 (zh) 多潛能細胞-2
WO2004075315A3 (fr) Batterie contenant une matiere fibreuse
WO2003035886A3 (fr) Preparation d'heparine a partir de cultures de mastocytes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP